RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
In addition to publishing numerous reviews of opera performances and concerts, Adorno's Four Songs for medium voice and piano, Op. 3, was performed in Berlin in January 1929. Between 1928 and 1930, Adorno took on a greater role within the editorial committee of the Musikblätter des Anbruchs. In a proposal for transforming the journal, he sought to use Anbruch to champion radical modern music against what he called the "stabilized music" of Pfitzner, the later Richard Strauss, as well as the neoclassicism of Stravinsky and Hindemith. During this period he published the essays "Night Music," "On Twelve-Tone Technique," and "Reaction and Progress." Yet his reservations about twelve-tone orthodoxy became steadily more pronounced. According to Adorno, twelve-tone technique's use of atonality can no more be regarded as an authoritative canon than can tonality be relied on to provide instructions for the composer. At this time Adorno struck up a correspondence with the composer Ernst Krenek, discussing problems of atonality and the twelve-tone technique. In a 1934 letter, he sounded a related criticism of Schoenberg:
=== MeSH D12.644.360 – intracellular signaling peptides and proteins === MeSH D12.644.360.011 – activating transcription factor 6 MeSH D12.644.360.024 – adaptor proteins, signal transducing MeSH D12.644.360.024.264 – caveolin 1 MeSH D12.644.360.024.272 – caveolin 2 MeSH D12.644.360.024.280 – cortactin MeSH D12.644.360.024.295 – crk-associated substrate protein MeSH D12.644.360.024.297 – grb2 adaptor protein MeSH D12.644.360.024.298 – grb7 adaptor protein MeSH D12.644.360.024.300 – grb10 adaptor protein MeSH D12.644.360.024.301 – interferon-stimulated gene factor 3 MeSH D12.644.360.024.301.500 – interferon-stimulated gene factor 3, alpha subunit MeSH D12.644.360.024.301.500.500 – stat1 transcription factor MeSH D12.644.360.024.301.500.750 – stat2 transcription factor MeSH D12.644.360.024.301.750 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.303 – interferon regulatory factors MeSH D12.644.360.024.303.124 – interferon regulatory factor-1 MeSH D12.644.360.024.303.249 – interferon regulatory factor-2 MeSH D12.644.360.024.303.374 – interferon regulatory factor-3 MeSH D12.644.360.024.303.437 – interferon regulatory factor-7 MeSH D12.644.360.024.303.500 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.305 – pii nitrogen regulatory proteins MeSH D12.644.360.024.307 – paxillin MeSH D12.644.360.024.311 – protein inhibitors of activated STAT MeSH D12.644.360.024.313 – 14-3-3 proteins MeSH D12.644.360.024.318 – proto-oncogene proteins c-crk MeSH D12.644.360.024.326 – proto-oncogene proteins c-vav MeSH D12.644.360.024.334 – smad proteins MeSH D12.644.360.024.334.200 – smad proteins, inhibitory MeSH D12.644.360.024.334.200.600 – smad6 protein MeSH D12.644.360.024.334.200.700 – smad7 protein MeSH D12.644.360.024.334.500 – smad proteins, receptor-regulated MeSH D12.644.360.024.334.500.100 – smad1 protein MeSH D12.644.360.024.334.500.200 – smad2 protein MeSH D12.644.360.024.334.500.300 – smad3 protein MeSH D12.644.360.024.334.500.500 – smad5 protein MeSH D12.644.360.024.334.500.800 – smad8 protein MeSH D12.644.360.024.334.750 – smad4 protein MeSH D12.644.360.024.342 – stat transcription factors MeSH D12.644.360.024.342.100 – stat1 transcription factor MeSH D12.644.360.024.342.200 – stat2 transcription factor MeSH D12.644.360.024.342.300 – stat3 transcription factor MeSH D12.644.360.024.342.400 – stat4 transcription factor MeSH D12.644.360.024.342.500 – stat5 transcription factor MeSH D12.644.360.024.342.600 – stat6 transcription factor MeSH D12.644.360.024.374 – suppressor of cytokine signaling proteins MeSH D12.644.360.024.500 – tumor necrosis factor receptor-associated peptides and proteins MeSH D12.644.360.024.500.500 – tnf receptor-associated factor 1 MeSH D12.644.360.024.500.750 – tnf receptor-associated factor 2 MeSH D12.644.360.024.500.875 – tnf receptor-associated factor 3 MeSH D12.644.360.024.500.937 – tnf receptor-associated factor 5 MeSH D12.644.360.024.500.968 – tnf receptor-associated factor 6 MeSH D12.644.360.050 – adenylate cyclase MeSH D12.644.360.075 – apoptosis regulatory proteins MeSH D12.644.360.075.311 – apoptosis inducing factor MeSH D12.644.360.075.405 – caspases MeSH D12.644.360.075.405.200 – caspase 1 MeSH D12.644.360.075.437 – inhibitor of apoptosis proteins MeSH D12.644.360.075.437.500 – neuronal apoptosis-inhibitory protein MeSH D12.644.360.075.437.750 – x-linked inhibitor of apoptosis protein MeSH D12.644.360.075.718 – proto-oncogene proteins c-bcl-2 MeSH D12.644.360.075.718.100 – bcl-associated death protein MeSH D12.644.360.075.718.400 – bcl-2-associated x protein MeSH D12.644.360.075.718.750 – bcl-2 homologous antagonist-killer protein MeSH D12.644.360.075.718.937 – bcl-x protein MeSH D12.644.360.075.718.968 – bh3 interacting domain death agonist protein MeSH D12.644.360.100 – ca(2+)-calmodulin dependent protein kinase MeSH D12.644.360.100.500 – myosin-light-chain kinase MeSH D12.644.360.150 – casein kinases MeSH D12.644.360.150.300 – casein kinase i MeSH D12.644.360.150.300.100 – casein kinase ialpha MeSH D12.644.360.150.300.200 – casein kinase idelta MeSH D12.644.360.150.300.300 – casein kinase iepsilon MeSH D12.644.360.150.600 – casein kinase ii MeSH D12.644.360.200 – cyclic nucleotide-regulated protein kinases MeSH D12.644.360.200.125 – cyclic amp-dependent protein kinases MeSH D12.644.360.200.125.500 – beta-adrenergic receptor kinase MeSH D12.644.360.200.150 – cyclic gmp-dependent protein kinases MeSH D12.644.360.200.575 – protamine kinase MeSH D12.644.360.250 – cyclin-dependent kinases MeSH D12.644.360.250.067 – cdc2-cdc28 kinases MeSH D12.644.360.250.067.249 – cdc2 protein kinase MeSH D12.644.360.250.067.500 – cdc28 protein kinase, s cerevisiae MeSH D12.644.360.250.067.875 – cyclin-dependent kinase 5 MeSH D12.644.360.250.067.900 – cyclin-dependent kinase 9 MeSH D12.644.360.250.323 – cyclin-dependent kinase 2 MeSH D12.644.360.250.451 – cyclin-dependent kinase 4 MeSH D12.644.360.250.515 – cyclin-dependent kinase 6 MeSH D12.644.360.250.580 – maturation-promoting factor MeSH D12.644.360.250.580.500 – cdc2 protein kinase MeSH D12.644.360.275 – eif-2 kinase MeSH D12.644.360.287 – focal adhesion protein-tyrosine kinases MeSH D12.644.360.300 – glycogen synthase kinases MeSH D12.644.360.300.500 – glycogen synthase kinase 3 MeSH D12.644.360.325 – gtp-binding protein regulators MeSH D12.644.360.325.150 – gtpase-activating proteins MeSH D12.644.360.325.150.100 – chimerin proteins MeSH D12.644.360.325.150.100.200 – chimerin 1 MeSH D12.644.360.325.150.300 – eukaryotic initiation factor-5 MeSH D12.644.360.325.150.500 – ras gtpase-activating proteins MeSH D12.644.360.325.150.500.460 – neurofibromin 1 MeSH D12.644.360.325.150.500.500 – p120 gtpase activating protein MeSH D12.644.360.325.150.750 – rgs proteins MeSH D12.644.360.325.225 – guanine nucleotide dissociation inhibitors MeSH D12.644.360.325.300 – guanine nucleotide exchange factors MeSH D12.644.360.325.300.200 – eukaryotic initiation factor-2b MeSH D12.644.360.325.300.300 – guanine nucleotide-releasing factor 2 MeSH D12.644.360.325.300.450 – proto-oncogene proteins c-vav MeSH D12.644.360.325.300.600 – ral guanine nucleotide exchange factor MeSH D12.644.360.325.300.700 – ras guanine nucleotide exchange factors MeSH D12.644.360.325.300.700.500 – ras-grf1 MeSH D12.644.360.325.300.700.700 – son of sevenless proteins MeSH D12.644.360.325.300.700.700.600 – son of sevenless protein, drosophila MeSH D12.644.360.325.300.700.700.630 – sos1 protein MeSH D12.644.360.350 – guanylate cyclase MeSH D12.644.360.375 – heterotrimeric gtp-binding proteins MeSH D12.644.360.375.100 – gtp-binding protein alpha subunits MeSH D12.644.360.375.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D12.644.360.375.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D12.644.360.375.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D12.644.360.375.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D12.644.360.375.100.400 – gtp-binding protein alpha subunits, gs MeSH D12.644.360.375.520 – gtp-binding protein beta subunits MeSH D12.644.360.375.730 – gtp-binding protein gamma subunits MeSH D12.644.360.375.940 – transducin MeSH D12.644.360.376 – i-kappa b kinase MeSH D12.644.360.378 – i-kappa b proteins MeSH D12.644.360.381 – intracellular calcium-sensing proteins MeSH D12.644.360.381.249 – calmodulin MeSH D12.644.360.381.311 – calnexin MeSH D12.644.360.381.374 – calreticulin MeSH D12.644.360.381.437 – gelsolin MeSH D12.644.360.381.500 – neuronal calcium-sensor proteins MeSH D12.644.360.381.500.124 – guanylate cyclase-activating proteins MeSH D12.644.360.381.500.249 – hippocalcin MeSH D12.644.360.381.500.374 – Kv channel-interacting proteins MeSH D12.644.360.381.500.500 – neurocalcin MeSH D12.644.360.381.500.750 – recoverin MeSH D12.644.360.400 – map kinase kinase kinases MeSH D12.644.360.400.100 – map kinase kinase kinase 1 MeSH D12.644.360.400.200 – map kinase kinase kinase 2 MeSH D12.644.360.400.300 – map kinase kinase kinase 3 MeSH D12.644.360.400.400 – map kinase kinase kinase 4 MeSH D12.644.360.400.500 – map kinase kinase kinase 5 MeSH D12.644.360.400.800 – proto-oncogene proteins c-mos MeSH D12.644.360.400.842 – raf kinases MeSH D12.644.360.400.842.249 – oncogene proteins v-raf MeSH D12.644.360.400.842.374 – proto-oncogene proteins b-raf MeSH D12.644.360.400.842.500 – proto-oncogene proteins c-raf MeSH D12.644.360.440 – mitogen-activated protein kinase kinases MeSH D12.644.360.440.100 – map kinase kinase 1 MeSH D12.644.360.440.200 – map kinase kinase 2 MeSH D12.644.360.440.300 – map kinase kinase 3 MeSH D12.644.360.440.400 – map kinase kinase 4 MeSH D12.644.360.440.500 – map kinase kinase 5 MeSH D12.644.360.440.600 – map kinase kinase 6 MeSH D12.644.360.440.700 – map kinase kinase 7 MeSH D12.644.360.450 – mitogen-activated protein kinases MeSH D12.644.360.450.169 – extracellular signal-regulated map kinases MeSH D12.644.360.450.169.500 – mitogen-activated protein kinase 1 MeSH D12.644.360.450.169.750 – mitogen-activated protein kinase 3 MeSH D12.644.360.450.169.875 – mitogen-activated protein kinase 6 MeSH D12.644.360.450.169.937 – mitogen-activated protein kinase 7 MeSH D12.644.360.450.340 – jnk mitogen-activated protein kinases MeSH D12.644.360.450.340.500 – mitogen-activated protein kinase 8 MeSH D12.644.360.450.340.750 – mitogen-activated protein kinase 9 MeSH D12.644.360.450.340.800 – mitogen-activated protein kinase 10 MeSH D12.644.360.450.835 – p38 mitogen-activated protein kinases MeSH D12.644.360.450.835.200 – mitogen-activated protein kinase 11 MeSH D12.644.360.450.835.400 – mitogen-activated protein kinase 12 MeSH D12.644.360.450.835.600 – mitogen-activated protein kinase 13 MeSH D12.644.360.450.835.800 – mitogen-activated protein kinase 14 MeSH D12.644.360.525 – monomeric gtp-binding proteins MeSH D12.644.360.525.100 – adp-ribosylation factors MeSH D12.644.360.525.100.100 – ADP-ribosylation factor 1 MeSH D12.644.360.525.400 – rab gtp-binding proteins MeSH D12.644.360.525.400.025 – rab1 gtp-binding proteins MeSH D12.644.360.525.400.050 – rab2 gtp-binding protein MeSH D12.644.360.525.400.100 – rab3 gtp-binding proteins MeSH D12.644.360.525.400.100.100 – rab3a gtp-binding protein MeSH D12.644.360.525.400.150 – rab4 gtp-binding proteins MeSH D12.644.360.525.400.200 – rab5 gtp-binding proteins MeSH D12.644.360.525.450 – ral gtp-binding proteins MeSH D12.644.360.525.462 – ran gtp-binding protein MeSH D12.644.360.525.475 – rap gtp-binding proteins MeSH D12.644.360.525.475.100 – rap1 gtp-binding proteins MeSH D12.644.360.525.500 – ras proteins MeSH D12.644.360.525.500.300 – oncogene protein p21(ras) MeSH D12.644.360.525.500.600 – proto-oncogene proteins p21(ras) MeSH D12.644.360.525.700 – rho gtp-binding proteins MeSH D12.644.360.525.700.050 – cdc42 gtp-binding protein MeSH D12.644.360.525.700.050.500 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D12.644.360.525.700.100 – rac gtp-binding proteins MeSH D12.644.360.525.700.100.100 – rac1 gtp-binding protein MeSH D12.644.360.525.700.200 – rhoa gtp-binding protein MeSH D12.644.360.525.700.300 – rhob gtp-binding protein MeSH D12.644.360.543 – olfactory marker protein MeSH D12.644.360.562 – phosphatidylethanolamine binding protein MeSH D12.644.360.581 – phospholipase c gamma MeSH D12.644.360.600 – ribosomal protein s6 kinases MeSH D12.644.360.600.249 – ribosomal protein s6 kinases, 70-kda MeSH D12.644.360.600.500 – ribosomal protein s6 kinases, 90-kda
=== Prostate cancer === In males aged 55 years old and over finasteride decreases the risk of low-grade prostate cancer but may increase the risk of high-grade prostate cancer and has no effect on overall survival. A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitors. A follow-up study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests the reduction in prostate cancer is maintained even after discontinuation of treatment. However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this. No impact of 5-α-reductase inhibitor on survival has been found in people with prostate cancer.
=== Early expansion, franchising and sale === The company had four restaurants by the time of Church Sr.'s death in 1956. After his death, family members took over operations. In 1962, with Church Sr.'s son Bill Church Jr. as top executive, there were eight restaurants in San Antonio. To begin expanding and franchising in 1965, Church Jr. and his brother Richard developed a signature marinade that could be prepared at any location. Former vacuum cleaner salesman J. David Bamberger, who first met Church Jr. when he joined Bamberger's vacuum cleaner distributorship, joined Church's Chicken in 1965 to oversee the franchising. In 1967, the chain opened restaurants in five Texan cities outside of San Antonio and operated 17 restaurants in 1968. In 1966, a contract between Church's Fried Chicken, Inc. and Jim Dandy Fast Foods, Inc. gave Jim Dandy the right to use the trade names and trademarks "Church's Fried Chicken" or "Church's" within fifty miles of Houston's city hall and within the city limits of Galveston, Texas for ten years, as long as Church's Chicken received the agreed upon royalties. In 1968, the Church family sold the company, which became incorporated and went public in 1969. By the end of 1968, there were more than 100 Church's Chicken restaurants in seven states, making the chain the first from Texas to become a national one. Between 1969 and 1974, Church's Chicken gained 387 more restaurants. In the late 1970s, the chain briefly operated a hamburger franchise in Texas called G.W. Jrs. The roughly 60 locations were shuttered in 1985. In 1980, Church Jr.
Sources: en.wikipedia.org
==== Ethyl carbamate ==== Urethane (ethyl carbamate) was once produced commercially in the United States as a chemotherapy agent and for other medicinal purposes. It was found to be toxic and largely ineffective. It is occasionally used in veterinary medicine in combination with other drugs to produce anesthesia.
== Organization == By NIGMS program mandate, Glue Grant consortia must contain core resources and bridging projects. The EFI consists of six scientific cores which provide bioinformatic, structural, computational, and data management expertise to facilitate functional predictions for enzymes of unknown function targeted by the EFI. At the beginning of the grant, these predictions were tested by five Bridging Projects representing the amidohydrolase, enolase, GST, HAD, and isoprenoid synthase enzyme superfamilies. Three Bridging Projects now remain. In addition, the Anaerobic Enzymology Pilot Project was added in 2014 to explore the Radical SAM superfamily and Glycyl Radical Enzyme superfamily.
== Use as a biomarker == Dinosterol is used as a biomarker for organic matter derived from dinoflagellates in sediments and seawater. Biomarkers are organic compounds that are indicative of former life in sediments, seawater and oil. The presence of the saturated hydrocarbon counterpart, dinosterane, is used as evidence that some of the organic matter present in ancient sediments may have been derived from dinoflagellates.
Sources: en.wikipedia.org
In 1972, eight remarkably preserved mummies were discovered at an abandoned Inuit settlement called Qilakitsoq, in Greenland. The "Greenland Mummies" consisted of a six-month-old baby, a four-year-old boy, and six women of various ages, who died around 500 years ago. Their bodies were naturally mummified by the sub-zero temperatures and dry winds in the cave in which they were found.
== Pathophysiology == The cause of the disease is the lack of a fully functional insulin receptor, which has a profound effect during fetal development and thereafter. In one case, it was found (by culturing pancreatic cells) that the receptor produced by the mutant allele is only about 15% as effective as the normal receptor. The beta cells in the pancreas, which make and store insulin and release it on an as-needed basis, are often found to be very large or numerous. The role of insulin in the body is to facilitate the entrance of glucose into the cell. Once insulin binds to the insulin receptors on the cell surface, the insulin receptors will send a signal that will ultimately bring the glucose transporter protein GLUT4 to attach to the cell membrane. Additionally, once insulin is bound to the insulin receptors, it will also initiate several signaling cascades that will promote cell growth and differentiation, protein synthesis, glucose synthesis, and the inhibition of gluconeogenesis through several metabolic pathways. A malfunctioning insulin receptor would thus not be able to properly initiate the signaling cascades for the aforementioned cellular processes. Many of the problems associated with Donohue syndrome may be due to the insulin receptor binding the insulin-like growth factor, regulating the growth of the embryo, in addition to its well-known role in the regulation of blood sugar.
In a bioassay, hPL mimics the action of prolactin, yet it is unclear whether hPL has any role in human lactation. Metabolic: ↓ maternal insulin sensitivity (insulin resistance), leading to an increase in maternal blood glucose levels. ↓ maternal glucose utilization, which helps ensure adequate fetal nutrition (the mother responds by increasing beta cells). Chronic hypoglycemia leads to a rise in hPL. ↑ lipolysis with the release of free fatty acids. With fasting and release of hPL, free fatty acids become available for the mother as free fatty acids do not cross the placenta, so that relatively more glucose can be utilized by the fetus. With sustained fasting, maternal ketones formed from free fatty acids can cross the placenta and be used by the fetus. These functions help support fetal nutrition even in the case of maternal malnutrition. hPL is a potent agonist of the prolactin receptor and a weak agonist of the growth hormone receptor.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.